Research programme: psoriasis therapeutics - Malvern CosmeceuticsAlternative Names: MCL 007-01
Latest Information Update: 16 Jul 2016
At a glance
- Originator Malvern Cosmeceutics
- Mechanism of Action NF-kappa B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (Topical, Gel)
- 16 Jul 2016 No recent reports of development identified for research development in Psoriasis in United Kingdom (PO, Tablet)
- 28 May 2013 Early research in Psoriasis in United Kingdom (Topical)